Breast Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This prospective, randomized neoadjuvant trial evaluated DNA-based biomarkers for predicting carboplatin response in 187 patients with early, high-risk, HER2-negative breast cancer, using whole-exome sequencing to calculate CAAI, LOH fraction, and HRD status before treatment with paclitaxel ± carboplatin followed by epirubicin/cyclophosphamide. Among TNBC patients, pCR was 69% (24/35) with carboplatin versus 43% (16/37) without (p=0.036), and carboplatin significantly prolonged event-free survival (p=0.017), with low genomic LOH fraction identifying those with improved EFS (p=0.007). In HR+BC patients, pCR was 15% (9/60) versus 11% (6/55; p=0.59), but low residual cancer burden increased from 16% to 35% (p=0.033), and HRD-positive tumors showed higher pCR (5/8) than HRD-negative (4/47; p=0.002). The study concludes that DNA-based biomarkers have distinct predictive values across breast cancer subtypes, with low LOH fraction guiding carboplatin use in TNBC and HRD in HR+BC.
10.1158/1078-0432.CCR-26-2212
Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505).
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This noninferiority randomized trial compared hypofractionated (42.56 Gy in 16 fractions) versus conventional (50 Gy in 25 fractions) postmastectomy radiation therapy in 898 women with breast cancer undergoing immediate or delayed breast reconstruction, with a median follow-up of 3.9 years and 825 evaluable for the primary endpoint. The primary outcome was a composite 24-month reconstruction complication rate, which was 12.3% (52/422) with hypofractionation versus 10.2% (41/403) with conventional therapy, yielding a difference of -2.1% (95% CI, -6.5 to 2.2), within the prespecified 10% noninferiority margin. Complication rates were higher with implant-only versus autologous reconstruction (odds ratio = 1.65), and 36-month locoregional recurrence rates were low and not significantly different (1.5% vs 2.2%). The authors conclude that a 16-fraction hypofractionated PMRT course is safe and noninferior to conventional PMRT in women undergoing breast reconstruction after mastectomy.
10.1200/JCO-26-00474
Oct 05 – Oct 12, 2026
Impact of Primary Prophylactic Colony-Stimulating Factor Delivery Method on Febrile Neutropenia: Secondary Analysis of a Pragmatic Cluster Randomized Clinical Trial.
JCO ONCOL PRACT · Q1 JOURNAL - RANK #81/326
This secondary analysis of the SWOG S1415CD pragmatic cluster-randomized trial evaluated whether primary prophylactic colony-stimulating factor delivery method affects febrile neutropenia incidence in 1,713 women receiving first-line breast cancer chemotherapy. Patients received PP-CSF via in-clinic administration (45%), on-body device (50%), or home self-injection (5%), with FN occurring in 3.8%, 5.0%, and 6.4% respectively. FN was significantly associated with high-risk regimens (OR 2.97) and poor performance status (OR 4.99) but not delivery method or agent. The authors conclude that FN rates are low regardless of delivery method and that delivery decisions may be guided by patient-centered factors.
10.1200/OP-26-00296
Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2-Low Breast Cancer.
MEDCOMM · Q1 JOURNAL - RANK #14/195TOP-TIER
This prospective single-arm phase II trial evaluated neoadjuvant disitamab vedotin plus penpulimab in 20 patients with Stage II-III HER2-low breast cancer, administering six cycles every three weeks before surgery. In the intention-to-treat population, the pathologic complete response rate was 20.0% (4/20; 95% CI, 5.7-43.7%) and the objective response rate was 45.0% (9/20; 95% CI, 23.1-68.5%). Grade ≥3 adverse events occurred in 25.0% with no treatment-related deaths, and exploratory multiomics analyses identified immune-active microenvironment features associated with pCR. The authors conclude the combination shows preliminary antitumor activity with manageable safety, but the small sample size and wide confidence intervals preclude definitive conclusions and warrant validation in larger randomized trials.
10.1002/mco2.70988
Sep 28 – Oct 05, 2026
Effect of dose-dense adjuvant chemotherapy in patients with node-positive early breast cancer according to estrogen receptor levels: an exploratory analysis of the GIM2 trial.
BREAST · Q1 JOURNAL - RANK #4/140
This exploratory analysis of the phase III GIM2 trial evaluated whether estrogen receptor (ER) expression levels predict benefit from dose-dense (DD) adjuvant chemotherapy in 1709 patients with node-positive early breast cancer randomized to DD versus standard-interval anthracycline-paclitaxel. ER expression was categorized as ER 0, ER-low (1-10%), ER-intermediate (11-50%), and ER-high (>50%), and associations with invasive disease-free survival (iDFS) and overall survival (OS) were assessed using multivariable Cox models and STEPP. At 15 years, iDFS rates were 48%, 59%, 56%, and 59% (p=0.001) and OS rates were 72%, 71%, 68%, and 75% (p<0.001) across ER categories, with no significant interaction between ER levels and treatment effect. The authors conclude that ER expression is prognostic but does not identify differential benefit from DD chemotherapy, supporting DD chemotherapy as an effective adjuvant option across the ER spectrum.
10.1016/j.breast.2026.104942
Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.
BRIT J CANCER · Q1 JOURNAL - RANK #47/326
This modular Phase 1 trial evaluated ceralasertib, an ATR inhibitor, alone and combined with olaparib in 142 patients with advanced solid tumours, including dose escalation (Part A1: ceralasertib monotherapy; Part A2: combination) and dose expansion in PARPi-naïve BRCA1/2-mutant HER2-negative breast cancer (Part B3) and BRCA1/2 wild-type triple-negative breast cancer (Part B4). The combination recommended Phase 2 dose was ceralasertib 160 mg once-daily days 1-7 plus olaparib 300 mg twice-daily continuously. Grade ≥3 treatment-emergent adverse events occurred in 43.2% and 36.0% of Parts B3 and B4, with objective response rates of 0% (Part A1), 16.4% (Part A2), 37.8% (Part B3), and 0% (Part B4). The authors concluded that ceralasertib-olaparib had manageable safety and preliminary antitumour activity in PARPi-naïve BRCA1/2-mutant HER2-negative breast cancer.
10.1038/s41416-026-03601-z
Giredestrant plus Everolimus in Advanced Breast Cancer.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 3, open-label, randomized trial evaluated giredestrant plus everolimus versus standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who progressed after CDK4/6 inhibitor plus endocrine therapy. Among 373 randomized patients, 207 had ESR1-mutated tumors; median progression-free survival was 10.0 vs 5.5 months (HR 0.38; 95% CI 0.27-0.54; P<0.001) in that subgroup and 8.8 vs 5.5 months (HR 0.56; 95% CI 0.44-0.71; P<0.001) overall. Adverse events occurred in 98.9% vs 96.8%, with stomatitis, diarrhea, and anemia most common. The all-oral giredestrant-everolimus regimen significantly prolonged progression-free survival, mainly in ESR1-mutated tumors, with similar toxicity to standard therapy-everolimus.
10.1056/NEJMoa2602457
A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018).
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This first-in-human phase I trial evaluated F0024 (FDA018), a TROP2-directed antibody-drug conjugate, in 67 patients with advanced solid tumors, including a triple-negative breast cancer expansion cohort. Participants received intravenous F0024 at 2.5-15 mg/kg in dose escalation, with TNBC expansion cohorts receiving 10 or 12 mg/kg to assess efficacy and safety. Notable antitumor activity occurred from 5 mg/kg, with an ORR of 66.7% at 10 mg/kg in escalation and 37.9% with median PFS of 10.5 months in TNBC; grade ≥3 TRAEs occurred in 57.7% of pooled TNBC patients. The authors conclude F0024 showed promising antitumor activity with manageable hematologic toxicity, recommending 10 mg/kg as the phase II dose.
10.1016/j.ejca.2026.117063
Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015).
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This single-arm phase 2 trial evaluated neoadjuvant SHR-A1811, an anti-HER2 antibody-drug conjugate, in 66 patients with untreated hormone receptor-positive, HER2-low invasive breast cancer. Patients received intravenous SHR-A1811 at 6.4 mg/kg every three weeks for eight cycles, with objective response rate as the primary endpoint. The objective response rate was 81.5% (95% CI 70.0-90.1), exceeding the prespecified 66.0% threshold, while pathological complete response occurred in only 3.1% and residual cancer burden 0-1 in 9.2%; grade ≥3 treatment-related adverse events occurred in 37.9%. The authors conclude that SHR-A1811 monotherapy showed favorable response rates with manageable toxicity, suggesting a potential neoadjuvant option pending further randomized trials.
10.1038/s41467-026-77041-x
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.
BREAST CANCER RES · Q1 JOURNAL - RANK #57/326
This post-hoc exploratory analysis of the randomized OptiTROP-Breast01 trial evaluated the safety profile of sacituzumab tirumotecan (sac-TMT) versus treatment of physician’s choice (TPC) in 262 patients with previously treated metastatic triple-negative breast cancer (130 sac-TMT, 132 TPC). The study characterized adverse events, focusing on hematologic toxicities and stomatitis, with median onset of grade ≥3 key AEs within the first two cycles and most patients recovering to grade ≤2 within 14 days. Efficacy was comparable across subgroups with early/late or no dose reduction, and treatment-related AE incidence decreased over time among patients treated >7 months. The authors concluded that sac-TMT has a manageable safety profile with toxicities effectively managed through dose modification and supportive care without compromising efficacy.
10.1186/s13058-026-02339-z
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This randomized, non-inferiority, open-label, phase 3 trial at a national cancer center in China assessed 10-year outcomes of hypofractionated (43.5 Gy in 15 fractions) versus conventional (50 Gy in 25 fractions) postmastectomy radiotherapy in 820 high-risk breast cancer patients, with 810 analyzed (409 conventional, 401 hypofractionated) after exclusions. At a median follow-up of 11.5 years, 10-year cumulative locoregional recurrence was 10.3% (95% CI 7.3-13.3) with conventional versus 12.0% (8.8-15.2) with hypofractionated radiotherapy (HR 1.19, 95% CI 0.79-1.82). Grade 3 adverse events were rare and similar between groups, with no grade 4-5 events, brachial plexopathy, serious adverse events, or treatment-related deaths. The authors conclude that hypofractionated postmastectomy radiotherapy provides durable locoregional control with no increase in severe late adverse events, supporting its use as a more time-efficient option.
10.1016/S1470-2045(26)00297-4
Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This phase 3 stage of the RC48-C006 phase 2/3 trial evaluated disitamab vedotin (DV) versus lapatinib plus capecitabine (L+C) in patients with HER2-positive breast cancer with liver metastases (BCLM) previously treated with trastuzumab and taxanes. In this prospective, open-label, multicenter, randomized trial, 104 patients were assigned 1:1 to DV (n=53) or L+C (n=51). DV significantly improved blinded independent review committee-assessed progression-free survival versus L+C (median 9.9 vs 4.9 months; stratified HR 0.56; 95.48% CI 0.35-0.91; P=0.01), with similar grade ≥3 treatment-related adverse event rates (37.7% vs 36.0%). The authors conclude that DV is a treatment option for HER2-positive BCLM after trastuzumab and taxane therapy.
10.1038/s41467-026-75733-y
Sep 21 – Sep 28, 2026
Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study.
ADV THER · Q1 JOURNAL - RANK #82/352
This Phase III, randomized, double-blind, multicenter trial evaluated the efficacy and safety of biosimilar trastuzumab EG12014 versus reference trastuzumab in adults with HER2-positive early breast cancer. Patients received neoadjuvant epirubicin/cyclophosphamide followed by randomization to EG12014 or reference trastuzumab with paclitaxel, then adjuvant therapy. The primary endpoint of centrally assessed pathological complete response demonstrated equivalence: risk difference -0.004 (95% CI -0.072 to 0.065) within the EMA margin (-0.13 to 0.13), and relative risk 0.992 (90% CI 0.880-1.118) within the FDA margin (0.741-1.349). Secondary efficacy, safety, immunogenicity, and pharmacokinetic profiles were comparable, including after switching, concluding that EG12014 and reference trastuzumab have equivalent efficacy in this setting.
10.1007/s12325-026-03781-3
Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial.
ESMO OPEN · Q1 JOURNAL - RANK #36/326
The IMpassion050 trial is a phase III randomized, double-blind study evaluating the addition of atezolizumab to neoadjuvant pertuzumab, trastuzumab, and chemotherapy in patients with high-risk HER2-positive early breast cancer. Patients were randomized 1:1 to atezolizumab or placebo, with postsurgery continuation of atezolizumab/placebo plus pertuzumab and trastuzumab for up to one year, and those with residual disease could switch to T-DM1 plus atezolizumab/placebo for 14 cycles. At a median follow-up of approximately 44 months, 3-year event-free survival was 91.4% with atezolizumab versus 89.0% with placebo (stratified HR 0.90, 95% CI 0.50-1.59), and 3-year disease-free survival among 434 patients who had surgery and postneoadjuvant therapy was 92.9% versus 88.5% (HR 0.71, 95% CI 0.38-1.32). The authors conclude that there were no significant improvements in EFS or DFS with the addition of atezolizumab, and safety remained consistent with known profiles of the study drugs.
10.1016/j.esmoop.2026.108541
Effectiveness of a novel low-level laser therapy protocol in managing breast cancer-related lymphedema.
LASER MED SCI · Q1 JOURNAL - RANK #78/312
This randomized controlled trial investigated the effects of low-level laser therapy (LLLT) at 904 nm and 650 nm versus sham treatment on breast cancer-related lymphedema in 46 patients. The study measured lymphatic function via ICG lymphography, subcutaneous thickness and tissue stiffness via ultrasonography and shear wave elastography, and fluid status via multifrequency bioelectrical impedance analysis and tissue dielectric constant. No significant between-group differences were found for lymphatic, fluid, or bioimpedance outcomes, though a significant between-group difference in upper-lateral shear wave velocity ratio change was observed (p=0.029), with greater reduction in the 904 nm group than the 650 nm group (adjusted p=0.026). The authors conclude that adding LLLT to conventional decongestive therapy did not produce significant additional effects on fluid or lymphatic outcomes, but site-specific reductions in tissue stiffness suggest a potential wavelength-dependent effect requiring further study.
10.1007/s10103-026-05045-6
Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
The STESIDES phase 1 trial evaluated the oral CYP11A1 inhibitor ODM-209 in 38 heavily pretreated patients with metastatic castration-resistant prostate cancer (n=34) and advanced breast cancer (n=4), using a 3+3 dose-finding design with glucocorticoid and mineralocorticoid replacement. Primary endpoints were dose-limiting toxicities and adverse events, with secondary endpoints including pharmacodynamics and clinical response. All participants experienced adverse events, most commonly fatigue (53%) and peripheral edema (34%), with grade ≥3 events in 24% and serious adrenal insufficiency in 8%. ODM-209 showed activity in mCRPC, with a 29% PSA50 response rate overall and 47% in patients with AR-LBD mutations, but no responses in advanced breast cancer.
10.1016/j.ejca.2026.117041
Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This phase 2, single-arm, open-label prospective clinical trial evaluated neoadjuvant zanidatamab, a dual HER2-directed bispecific antibody, in 20 patients with early-stage HER2-positive breast cancer (1-3 cm, node-negative). Patients received zanidatamab 20 mg/kg every two weeks for 6 or 10 doses, with 14 also receiving endocrine therapy; the primary endpoint was pathologic complete response (pCR). At surgery, 6 patients (30%) achieved pCR, meeting the prespecified target, and 4 (20%) had limited residual cancer burden (RCB-1); treatment was well tolerated with significant tumor size and volume decreases at 6 weeks. The authors conclude that de-escalation to HER2-targeted therapy alone may be feasible, though further research is needed to refine patient selection.
10.1038/s41467-026-76662-6
Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
VIOLETTE (NCT03330847) was a phase II randomized trial assessing olaparib alone or combined with ceralasertib or adavosertib as second-/third-line treatment for advanced triple-negative breast cancer across three molecular strata. Patients (n=273) were randomized 1:1:1, stratified by BRCA1/2m, non-BRCA1/2m HRRm, or non-HRRm status, with progression-free survival as the primary endpoint. Median PFS for ceralasertib plus olaparib was 7.4, 3.9, and 3.6 months in the three strata respectively and did not differ significantly from olaparib alone. In the non-HRRm group, objective response rate was significantly improved (15.4% vs 3.9%; OR 4.45; P=0.0425), though without PFS benefit.
10.1158/1078-0432.CCR-26-1066
Multimodal Japanese-style acupuncture and moxibustion for taxane-related chemotherapy-induced peripheral neuropathy in breast cancer survivors.
SUPPORT CARE CANCER · Q1 JOURNAL - RANK #17/173
This single-center, single-arm prospective clinical trial evaluated multimodal Japanese-style acupuncture and moxibustion (MJAM) for taxane-related chemotherapy-induced peripheral neuropathy (CIPN) in 30 breast cancer survivors who had completed curative treatment. Participants received 12 weekly MJAM sessions combining filiform needle acupuncture, Teishin therapy, motion-style acupuncture, indirect moxibustion, hot packs, and self-care instruction, with the primary endpoint being change in Brief Pain Inventory (BPI) item 5 from baseline to week 16. BPI item 5 scores significantly decreased over time: -0.1 at week 4 (p=0.56), -0.7 at week 8 (p=0.008), -1.1 at week 12 (p=0.0003), and -1.2 at week 16 (p<0.0001), with 93.3% treatment completion and only mild grade 1 adverse events in 30% of participants. The authors concluded that MJAM was safe, feasible, and associated with reduced pain in breast cancer survivors with persistent taxane-related CIPN, warranting a confirmatory randomized clinical trial.
10.1007/s00520-026-11237-1
Sep 14 – Sep 21, 2026
70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This exploratory subgroup analysis of the MINDACT trial evaluated the 70-gene signature MammaPrint in patients over 50 years with stage I-II HR+/HER2- breast cancer and clinical high/genomic low-risk. Among 868 patients, 8-year distant metastasis-free survival without adjuvant chemotherapy was 87.9% for tumors >2 cm, 91.3% for grade 3 tumors, and 89.6% for nodal involvement, with absolute ACT benefit of 1.2%, -2.2%, and 0.7%, respectively. The study confirms the prognostic performance of the 70-gene signature in high-risk clinical-pathological subgroups. These findings support omitting adjuvant chemotherapy in this genomic low-risk population regardless of high-risk features.
10.1016/j.ejca.2026.117044
Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study.
BREAST CANCER-TOKYO · Q1 JOURNAL - RANK #26/140
This interventional prospective study evaluated partial breast proton beam therapy (PB-PBT) without tumor resection as an alternative to partial mastectomy for low-risk early-stage breast cancer. Eleven patients with cT1N0M0 invasive ductal carcinoma received 62.4 Gy (RBE) in 26 fractions, with follow-up every 3-6 months; median follow-up was 82 months. No local recurrences occurred in patients followed ≥5 years, with only Grade 1-2 dermatitis and Grade 1 telangiectasia observed. The authors conclude PB-PBT without lumpectomy may be a viable radiation-only treatment option within specific criteria.
10.1007/s12282-026-01916-6
E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114.
BREAST CANCER RES · Q1 JOURNAL - RANK #57/326
This phase 1 dose-expansion study evaluated E7389-LF as first-line chemotherapy in 26 Japanese patients with metastatic/advanced HER2-negative breast cancer, assessing safety, efficacy, and biomarker changes per RECIST v1.1. Treatment-related adverse events included alopecia (88.5%), neutropenia (88.5%; grade ≥3 76.9%), and thrombocytopenia (84.6%; grade ≥3 34.6%), with 3 discontinuations. The objective response rate was 30.8% (8 confirmed partial responses), median progression-free survival was 8.1 months overall (9.8 months in triple-negative subgroup), and overall survival was not reached at 22.7 months. The authors conclude E7389-LF shows antitumor activity and manageable safety, warranting further study as first-line therapy for HER2-negative breast cancer.
10.1186/s13058-026-02295-8
Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial.
BREAST · Q1 JOURNAL - RANK #4/140
This updated subgroup analysis of the KEYNOTE-522 randomized clinical trial evaluated perioperative pembrolizumab plus chemotherapy in 216 participants with early triple-negative breast cancer enrolled in Asia. Participants were randomized 2:1 to neoadjuvant pembrolizumab or placebo plus chemotherapy for 8 cycles, followed by adjuvant pembrolizumab or placebo for up to 9 cycles after surgery. At 60 months, the pembrolizumab group showed improved event-free survival (87.4% vs 72.1%; HR 0.43, 95% CI 0.23-0.81) and overall survival (91.9% vs 81.1%; HR 0.41, 95% CI 0.19-0.86) compared to placebo. The authors conclude that these outcomes are consistent with the overall population and support perioperative pembrolizumab plus chemotherapy as standard care in this setting.
10.1016/j.breast.2026.104904
Sep 07 – Sep 14, 2026
Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.
JCO PRECIS ONCOL · Q1 JOURNAL - RANK #57/326
This prospective ctDNA substudy within the NSABP B-59/GeparDouze randomized trial evaluated a tumor-informed molecular residual disease assay in 160 patients with stage II/III triple-negative breast cancer receiving neoadjuvant chemotherapy with or without atezolizumab. Serial blood samples were collected at baseline, after neoadjuvant therapy, 3-6 weeks postsurgery, and at 12 and 24 months, with whole-exome sequencing used to generate patient-specific assays correlated with distant recurrence-free interval. Baseline ctDNA was detected in 96% (153/160) of patients, while postsurgery ctDNA was detected in only 6% (9/147); distant recurrence occurred in 77.8% of ctDNA-positive versus 5% of ctDNA-negative patients (HR 30.3, 95% CI 10.4-88.7; log-rank p<1E-16). The tumor-informed MRD assay demonstrated high baseline prevalence, marked clearance with neoadjuvant therapy, and strong prognostic utility of post-treatment ctDNA-positive status for distant recurrence in early TNBC.
10.1200/PO-26-00114
Efficacy and Safety of Intraventricular Thiotepa in Combination With Methotrexate for Leptomeningeal Metastasis From Breast Cancer (NJMU-BC04): A Single-Arm Phase II Study.
MEDCOMM · Q1 JOURNAL - RANK #14/195TOP-TIER
This single-arm phase II trial evaluated intraventricular thiotepa combined with methotrexate in adult patients with breast cancer-related leptomeningeal metastasis. The primary endpoint was met with an intracranial objective response rate of 45.8% (11/24; 95% CI 25.55–67.18%) and an intracranial disease control rate of 58.3% (14/24; 95% CI 36.64–77.89%). Median intracranial progression-free survival and overall survival were 7.9 months (95% CI 5.3–not estimable) and 11.7 months (95% CI 5.7–not estimable), respectively. Grade 3–4 treatment-related adverse events occurred in 62.5% (15/24) of patients, most commonly thrombocytopenia (37.5%) and leukopenia (33.3%), with no grade 5 toxicities, supporting feasibility and a preliminary clinical benefit signal.
10.1002/mco2.71014
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort.
ESMO OPEN · Q1 JOURNAL - RANK #36/326
This prespecified analysis of the TROPION-Breast01 China cohort evaluated datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy in 83 patients with previously treated, inoperable/metastatic HR+/HER2- breast cancer. Patients were randomized 1:1 to Dato-DXd (6 mg/kg every 3 weeks) or chemotherapy (eribulin/capecitabine/vinorelbine/gemcitabine), with dual primary endpoints of PFS by BICR and OS. PFS numerically favored Dato-DXd (HR 0.54, 95% CI 0.30-0.96; median 8.1 vs 4.2 months), while OS showed no significant difference (HR 0.83, 95% CI 0.49-1.43). Grade ≥3 TRAEs were lower with Dato-DXd (29.5% vs 58.3%), supporting it as a new treatment option for Chinese patients.
10.1016/j.esmoop.2026.108538
Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This Phase III, open-label, multicenter randomized controlled trial evaluated the safety and efficacy of trastuzumab botidotin versus trastuzumab emtansine in 365 adult patients with HER2-positive unresectable/metastatic breast cancer who had prior trastuzumab and taxane therapy. Patients were randomized 1:1, with the primary endpoint being progression-free survival assessed by blinded independent central review using intention-to-treat analysis. Trastuzumab botidotin demonstrated significantly longer PFS compared to trastuzumab emtansine (median 11.1 vs 4.4 months; HR 0.39, 95% CI 0.30-0.51; P<.0001), with objective response rates of 76.9% versus 53.0%, though overall survival data were immature. The study concluded that trastuzumab botidotin resulted in significantly longer PFS with a distinct safety profile, including higher ocular adverse events but lower pulmonary, hematologic, hepatic, and GI toxicities.
10.1200/JCO-26-00602
First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations.
DRUG DES DEV THER · Q1 JOURNAL - RANK #44/352
This Phase 1, open-label, multicenter study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the PARP inhibitor HWH340 in patients with advanced solid tumors, enrolling 77 patients across dose-escalation, multiple-dose escalation, and dose-expansion stages. The study employed a 3+3 design for dose escalation and enrolled 42 patients in the dose-expansion phase, with cohorts enriched for homologous recombination repair gene mutations. No dose-limiting toxicities occurred, and the most common grade ≥3 treatment-related adverse events were neutropenia and anemia (14.3% each); among 41 evaluable patients, the objective response rate was 19.5% and disease control rate was 56.1%. The authors concluded that HWH340 was well-tolerated with promising antitumor activity, establishing 200 mg BID as the recommended Phase 2 dose, while noting that small sample size and heterogeneity necessitate further confirmation.
10.2147/DDDT.S606617
Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This randomized, double-blind phase 3 equivalence trial evaluated neoadjuvant pertuzumab biosimilar HLX11 versus reference pertuzumab, both combined with trastuzumab and docetaxel, in 908 patients with HER2-positive, hormone receptor-negative early-stage or locally advanced breast cancer. Patients received 4 cycles of neoadjuvant therapy, followed by adjuvant treatment with HLX11 or EU-pertuzumab plus trastuzumab. BICR-assessed tpCR rates were 46.3% versus 45.8%, with a relative risk of 1.01 (90% CI 0.90-1.14) and relative difference of 0.47% (95% CI -5.99%-6.92%), meeting equivalence criteria; no clinically meaningful differences in efficacy, safety, PK, or immunogenicity were observed. Neoadjuvant HLX11 demonstrated similar tpCR and safety profiles compared with EU-pertuzumab in this breast cancer population.
10.1158/1078-0432.CCR-26-1604
Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This first-in-human, multicenter, open-label, non-randomized Phase 1 dose-escalation trial (NCT05013554) evaluated the safety, efficacy, pharmacokinetics, and pharmacodynamics of the HER2×CD3×CD28 trispecific T-cell engager SAR443216 in 40 participants with relapsed/refractory HER2-expressing solid tumors. The primary objective was to determine the maximum tolerated dose (MTD), with secondary objectives including PK, immunogenicity, and preliminary clinical activity. Treatment was administered intravenously at dose levels of 18-900 µg, with intraparticipant lead-in dosing; disease control rates were 34.5% and 36.4% in the 2-week and 3-week lead-in cohorts, respectively, with no objective responses observed and the MTD not reached. The study concluded that SAR443216 treatment was feasible and well tolerated, with manageable toxicity (97.5% any-grade TEAEs, 45% grade ≥3, 50% CRS), warranting further evaluation of its efficacy and safety.
10.1136/jitc-2025-014309
Aug 31 – Sep 07, 2026
Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This multicenter, phase 3 randomized clinical trial evaluated neoadjuvant anbenitamab plus HB1801 versus trastuzumab, pertuzumab, and docetaxel in 521 patients with stage II/III ERBB2-positive breast cancer. The primary endpoint was total pathological complete response (tpCR) assessed by blinded independent review. The tpCR rate was significantly higher in the investigational group (62.4% vs 51.2%; absolute difference 11.4 percentage points; 95% CI, 3.2-19.6; P=.004), with consistent benefit across subgroups. Grade 3/4 adverse events were similar (29.3% vs 28.3%), with no treatment-related deaths; the authors conclude the new combination improves efficacy with manageable safety, warranting longer follow-up.
10.1001/jamaoncol.2026.3329
Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This multicenter, multinational, double-blinded randomized phase 3 trial (NSABP B-59/GeparDouze) evaluated the addition of atezolizumab to neoadjuvant chemotherapy in 1,550 patients with stage II-III triple-negative breast cancer (773 atezo, 777 placebo). The primary endpoint of event-free survival was not significantly improved with atezolizumab (HR 0.80, 95% CI 0.62-1.03, P=0.083; 4-year EFS difference 3.3%). Overall survival also showed no significant benefit (HR 0.86, 95% CI 0.62-1.19; 4-year difference 0.7%). Grade ≥3 adverse events occurred in 75.3% (atezo) versus 73.4% (placebo), with immune-related events in 27.6% versus 11.4%, respectively; exploratory subgroup analysis suggested benefit in basal-like immune-activated tumors and those with clinical lymph node involvement.
10.1038/s41591-026-04565-6
Effects of transcutaneous electrical acupoint stimulation versus acupressure on the trajectories of multidimensional adverse reactions to chemotherapy in breast cancer patients: a secondary analysis of a randomized controlled trial.
SUPPORT CARE CANCER · Q1 JOURNAL - RANK #17/173
This secondary analysis of a randomized controlled trial investigated the effects of transcutaneous electrical acupoint stimulation (TEAS) and self-acupressure (SA) on trajectories of multidimensional chemotherapy-induced adverse reactions in breast cancer patients. The study included 189 patients and used Group-Based Multi-Trajectory Model to identify symptom trajectories, followed by causal forest analysis to estimate average treatment effects. Two heterogeneous trajectories were identified: ‘High Symptom Burden-Persistent’ (n=101) and ‘Low Symptom Burden-Relieving’ (n=88). Both TEAS and SA significantly increased the probability of classification into the favorable trajectory, with average treatment effects of 0.147 (95% CI: 0.143-0.151) for TEAS and 0.176 (95% CI: 0.162-0.190) for SA, concluding both are effective non-pharmacological interventions.
10.1007/s00520-026-11168-x
Aug 24 – Aug 31, 2026
Prospective Clinical Trial on Expanding the Eligibility Criteria for Targeted Axillary Dissection after Neoadjuvant Systemic Therapy in Breast Cancers with Advanced Nodal Disease.
ANN SURG ONCOL · Q1 JOURNAL - RANK #39/312
This prospective clinical trial evaluated whether targeted axillary dissection (TAD) is noninferior to axillary dissection (AD) for nodal staging in breast cancer patients with advanced nodal disease (>3 metastatic nodes up to clinical N3) after neoadjuvant chemotherapy. Fifty-five patients were analyzed after 10 withdrew from the initial 65 recruited. The false negative rate (FNR) of TAD was 0%, with a technical success rate of 96%, clipped node detection of 100%, and axillary pathologic complete response rate of 49%. The authors conclude that TAD is highly accurate in this population and supports expanding eligibility to reduce AD-related morbidity.
10.1245/s10434-026-20132-2
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This multicenter randomized phase II trial (AZTEC) evaluated single-fraction (20 Gy) versus multi-fraction (24 Gy in three fractions) stereotactic ablative body radiotherapy (SABR) followed by atezolizumab in 54 women with advanced triple-negative breast cancer as first- or second-line treatment. The primary endpoint was progression-free survival (PFS), with secondary endpoints including response rates, overall survival, and safety. Median PFS was 2.5 months (90% CI: 1.7-4.5) for single-fraction and 3.1 months (90% CI: 1.8-3.9) for multi-fraction, with the null hypothesis (PFS of 2 months) not rejected in either arm; clinical benefit was observed in 20% and 25% of patients, respectively, all with oligometastatic disease. The combination was safe, but further efficacy testing is needed.
10.1038/s41467-026-75660-y
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This randomized phase III trial (OlympiA) compared one year of adjuvant olaparib versus placebo in 1,836 patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. At a median follow-up of 6.1 years, olaparib maintained significant improvements in invasive disease-free survival (HR=0.65, 95% CI: 0.53-0.78), distant disease-free survival (HR=0.65, 95% CI: 0.53-0.81), and overall survival (HR=0.72, 95% CI: 0.56-0.93). The 6-year overall survival was 87.5% with olaparib versus 83.2% with placebo (difference 4.4%, 95% CI: 0.9-6.7%). The authors conclude that adjuvant olaparib provides ongoing clinically meaningful survival benefits with acceptable toxicity, supporting its continued use in this high-risk population.
10.1016/j.annonc.2026.08.002
Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This independent, external validation study (CATALINA) prospectively pooled data from seven randomized adjuvant trials to compare the prognostic performance of artificial intelligence (AI)-derived computational tumour-infiltrating lymphocyte (cTIL) scores with pathologist-scored stromal TILs (sTILs) in patients with early-stage triple-negative breast cancer (TNBC). The study deployed two locked AI pipelines on 2,244 digitized whole slide images, evaluating 1,759 patients, with 1,356 having complete data for analysis. cTIL scores showed modest correlation with sTILs (r=0.375-0.473) and were independently associated with 5-year invasive disease-free survival (hazard ratio [HR] 0.80 [95% CI 0.73-0.89]), distant disease-free survival (HR 0.77 [0.69-0.86]), and overall survival (HR 0.79 [0.70-0.88]), but did not incrementally improve prognostic models when sTIL scores were included. The authors conclude that cTIL scores offer a reproducible prognostic biomarker, particularly where pathologist assessment is unavailable, though they do not replace sTILs in fully equipped settings.
10.1016/S1470-2045(26)00339-6
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This secondary analysis of the phase 3 APHINITY randomized trial evaluated manual, digital, and AI-based stromal tumor-infiltrating lymphocyte (sTIL) scoring for prognostic and treatment-benefit stratification in 4262 HER2-positive breast cancer patients. The study assessed associations with invasive disease-free survival (primary outcome), distant recurrence-free interval, and overall survival using multivariable Cox models, subgroup analyses, and treatment-by-biomarker interaction terms. Manual scoring demonstrated high interobserver reproducibility (ICC 0.84), while higher TIL levels were associated with improved invasive disease-free survival across all methods (HRs 0.41-0.93), and pertuzumab benefit was greatest in node-positive, immune-high tumors (12.1 percentage point absolute improvement). The authors concluded that digital and AI methods provide consistent prognostic stratification with potential for treatment-benefit stratification, though AI spatial metrics offer complementary information requiring further validation.
10.1016/S1470-2045(26)00247-0
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This phase 1b/2 umbrella trial evaluated elacestrant plus everolimus in 73 patients with ER+/HER2- advanced breast cancer previously treated with endocrine therapy and CDK4/6 inhibitors. The phase 2 cohort (n=50) demonstrated a median progression-free survival of 8.3 months (95% CI: 4.0-10.2) across all patients, with consistent benefits observed regardless of ESR1 or PIK3CA mutation status. Adverse events were predominantly grade 1-2, with 6% of patients experiencing drug withdrawal and 2% requiring dose reduction due to toxicity. The authors conclude that this combination offers clinically meaningful activity and represents a potential all-oral endocrine therapy backbone for this patient population.
10.1158/1078-0432.CCR-26-1816
Ultrasound localisation microscopy predicts neoadjuvant chemotherapy response in patients with breast cancer.
EBIOMEDICINE · Q1 JOURNAL - RANK #13/195TOP-TIER
This prospective pilot study (NCT05445050) evaluated ultrasound localisation microscopy (ULM) as a predictive tool for pathological complete response (pCR) in 20 breast cancer patients undergoing neoadjuvant chemotherapy. Vascular features were extracted from ULM images using radiomics and used to classify therapy response with logistic regression. Patients with pCR (n=8) showed more pronounced vascular networks before therapy and greater vessel coverage changes after the first cycle compared to non-pCR patients (n=12) (26.97% vs 6.00%, p<0.01, effect size 2.21). ULM features predicted responses with up to 85% accuracy (AUC 0.85), outperforming tumour size and B-mode imaging, suggesting its potential to optimize treatment schedules.
10.1016/j.ebiom.2026.106442
Periductal myxoid stroma identifies ductal carcinoma in situ at risk of invasive recurrence.
JNCI-J NATL CANCER I · Q1 JOURNAL - RANK #44/326
This study evaluated whether periductal myxoid stroma in diagnostic hematoxylin-eosin sections predicts invasive recurrence among 711 DCIS patients from the randomized SweDCIS trial, who underwent breast-conserving surgery with or without radiotherapy. Two raters scored the proportion of DCIS ducts surrounded by myxoid stroma. Eighty patients developed ipsilateral invasive recurrence as first event post surgery. Cause-specific Cox regression revealed that an increase in myxoid stroma was associated with a higher risk of invasive recurrence (adjusted HR per 10% increase = 1.16 [1.04-1.28]; p = 0.005). The 20-year cumulative incidence of invasive recurrence was more than doubled for lesions with at least 10% myxoid stroma compared with those with less than 10% myxoid stroma (15.7% vs 7.1%). Periductal myxoid stroma may be a simple histologic marker for the invasive potential of DCIS.
10.1093/jnci/djag293
Aug 17 – Aug 24, 2026
Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial.
BREAST · Q1 JOURNAL - RANK #4/140
This prospective-retrospective secondary analysis of the phase III IDEAL trial evaluated the CanAssist Breast (CAB) biomarker for predicting late recurrence and benefit of extended endocrine therapy (EET) in HR+/HER2- early breast cancer. The study pooled 3,052 retrospective patients and 627 patients from the IDEAL trial (2.5 vs 5 years EET, 15-year follow-up). CAB classified patients into low-risk (≤9% recurrence risk) and high-risk (9.1-100%), with an ultra-high-risk (UHR) subgroup (>20%). Results showed CAB-UHR patients had improved distant recurrence-free survival (DRFS) with 5-year vs 2.5-year EET (ΔDRFS 10%) compared to low-risk (1%) and high-risk (1.5%) groups, identifying a UHR category benefiting from extended therapy.
10.1016/j.breast.2026.104903
Positive effect of methylphenidate for cancer-related cognitive impairment: a pilot randomized trial.
J PAIN SYMPTOM MANAG · Q1 JOURNAL - RANK #53/332
This pilot randomized, double-blind, placebo-controlled trial evaluated the feasibility of methylphenidate (MPH) for managing cancer-related cognitive impairment (CRCI) in women after breast cancer treatment. Twenty women with documented cognitive dysfunction were randomized to MPH (n=9) or placebo (n=11), receiving 10 mg/day for 14 days, increased to 20 mg/day for 14 days if tolerated, with assessments at Days 0, 15, and 29. The MPH group showed greater improvement in FACT-Cog Perceived Cognitive Impairments scores at Day 29 (mean difference=10.1, p=0.02), with no between-group differences in neuropsychological tests or worsening of physical, psychological, or sleep symptoms. The authors conclude MPH may have clinically relevant effects on perceived cognitive dysfunction, supporting evaluation in a phase III trial.
10.1016/j.jpainsymman.2026.08.010
The clinical value of clinical treatment score post-5 years in patients with premenopausal breast cancer: a retrospective analysis of ASTRRA trial.
BREAST · Q1 JOURNAL - RANK #4/140
This retrospective analysis of the ASTRRA randomized trial evaluated the prognostic performance of the Clinical Treatment Score post-5 years (CTS5) in 1028 premenopausal breast cancer patients who were event-free at 5 years. Patients were categorized into CTS5 risk groups, and late distant metastasis-free survival (DMFS) and overall survival were analyzed, including subgroup comparisons between tamoxifen-only and tamoxifen plus ovarian function suppression arms. The high-risk group had significantly worse late DMFS compared to the low-risk group (HR=3.32; 95% CI: 1.73-6.37; p<0.001), with late distant metastasis rates of 3.43% (low), 2.56% (intermediate), and 9.63% (high); the intermediate group showed no significant difference (HR=1.06; p=0.876). The authors concluded that unmodified CTS5 identifies high-risk patients but exhibits threshold inversions, making it unreliable for guiding extended therapy in premenopausal patients.
10.1016/j.breast.2026.104900
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
EA1181 (CompassHER2 pCR) is a single-arm, prospective clinical trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in 2,141 patients with stage II/IIIa HER2-positive breast cancer, with secondary analysis of pathologic complete response (pCR) rates and predictors. The overall pCR rate was 43.8%, with rates of 63.7% in HER2+/ER- and 32.4% in HER2+/ER+ tumors. Independent predictors of higher pCR included ER-negative or low expression, PR-negative or low expression, HER2 IHC 3+, weekly paclitaxel, and high HER2DX pCR scores. The study concluded that THP achieves high pCR rates in HER2+ breast cancer and that these predictors can inform risk stratification and treatment personalization.
10.1200/JCO-25-02255
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This is a preplanned biomarker analysis of the phase 3 RxPONDER randomized clinical trial, which prospectively assigned patients to endocrine therapy (ET) alone or with chemotherapy (CET) for HR-positive, HER2-negative, node-positive breast cancer. The analysis measured baseline serum estradiol, progesterone, FSH, LH, AMH, and inhibin B in 1556 participants aged <55 years to predict chemotherapy benefit. At a median follow-up, AMH ≥10 pg/ml showed a significant interaction with chemotherapy benefit for invasive disease-free survival (IDFS) (P=0.0034), with CET improving IDFS in 64% of women with normal ovarian reserve (HR 0.46, 95% CI 0.33-0.65) but not in those with low AMH (HR 1.27, 95% CI 0.81-1.99). The authors conclude that AMH refines patient selection for adjuvant chemotherapy, with low AMH indicating no benefit from CET.
10.1016/j.annonc.2026.05.697
Anthracycline-Free Neoadjuvant Therapy With Nab-Paclitaxel and Carboplatin in Non-Luminal Breast Cancer: A Single-Arm Clinical Trial.
INT J CANCER · Q1 JOURNAL - RANK #77/326
This prospective, single-center clinical trial (NEOPATH) evaluated the efficacy and safety of neoadjuvant nab-paclitaxel plus carboplatin with trastuzumab and pertuzumab in HER2-positive patients, for stage II-III non-luminal breast cancer. A total of 106 patients were enrolled, with 99 proceeding to surgery. The primary endpoint, pathological complete response (pCR) rate, was 41.41% overall, 33.78% in TNBC, and 64.00% in HER2-positive disease. The regimen demonstrated promising efficacy and was well-tolerated, with grade 3+ neutropenia as the most common adverse event (57%).
10.1002/ijc.70666